Joshua S. Benner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Joshua S. Benner has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
C. Yunis
Pfizer Inc, New York, NY, USA
1 shared publicationE. S. Johnson
Graunt & Co., LLC, Seattle, WA, USA
1 shared publicationHelen Mogun
1 shared publicationJ. García-Puig
Vascular Risk Unit, Division of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain
1 shared publicationJerry Avorn
1 shared publicationK. Changela
Pfizer Inc, New York, NY, USA
1 shared publication
Latest Publications
- Open Access
- 7 August 2008
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 62 (10) , 1484-1498
A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients’ modifiable risk factor profile
We assessed whether a novel programme to evaluate/communicate predicted coronary heart disease (CHD) risk could lower patients' predicted Framingham CHD risk vs. usual care. The Risk Evaluation and Communication Health Outcomes and Utilization Trial was a prospective, controlled, cluster-randomised trial in nine European countries, among patients at moderate cardiovascular risk. Following baseline assessments, physicians in the intervention group calculated patients' predicted CHD risk and were instructed to advise patients according to a risk evaluation/communication programme. Usual care physicians did not calculate patients' risk and provided usual care only. The primary end-point was Framingham 10-year CHD risk at 6 months with intervention vs. usual care. Of 1103 patients across 100 sites, 524 patients receiving intervention, and 461 receiving usual care, were analysed for efficacy. After 6 months, mean predicted risks were 12.5% with intervention, and 13.7% with usual care [odds ratio = 0.896; p = 0.001, adjusted for risk at baseline (17.2% intervention; 16.9% usual care) and other covariates]. The proportion of patients achieving both blood pressure and low-density lipoprotein cholesterol targets was significantly higher with intervention (25.4%) than usual care (14.1%; p < 0.001), and 29.3% of smokers in the intervention group quit smoking vs. 21.4% of those receiving usual care (p = 0.04). A physician-implemented CHD risk evaluation/communication programme improved patients' modifiable risk factor profile, and lowered predicted CHD risk compared with usual care. By combining this strategy with more intensive treatment to reduce residual modifiable risk, we believe that substantial improvements in cardiovascular disease prevention could be achieved in clinical practice.
- 7 August 2008
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 62 (10) , 1484-1498
Open AccessA novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients’ modifiable risk factor profile
We assessed whether a novel programme to evaluate/communicate predicted coronary heart disease (CHD) risk could lower patients' predicted Framingham CHD risk vs. usual care. The Risk Evaluation and Communication Health Outcomes and Utilization Trial was a prospective, controlled, cluster-randomised trial in nine European countries, among patients at moderate cardiovascular risk. Following baseline assessments, physicians in the intervention group calculated patients' predicted CHD risk and were instructed to advise patients according to a risk evaluation/communication programme. Usual care physicians did not calculate patients' risk and provided usual care only. The primary end-point was Framingham 10-year CHD risk at 6 months with intervention vs. usual care. Of 1103 patients across 100 sites, 524 patients receiving intervention, and 461 receiving usual care, were analysed for efficacy. After 6 months, mean predicted risks were 12.5% with intervention, and 13.7% with usual care [odds ratio = 0.896; p = 0.001, adjusted for risk at baseline (17.2% intervention; 16.9% usual care) and other covariates]. The proportion of patients achieving both blood pressure and low-density lipoprotein cholesterol targets was significantly higher with intervention (25.4%) than usual care (14.1%; p < 0.001), and 29.3% of smokers in the intervention group quit smoking vs. 21.4% of those receiving usual care (p = 0.04). A physician-implemented CHD risk evaluation/communication programme improved patients' modifiable risk factor profile, and lowered predicted CHD risk compared with usual care. By combining this strategy with more intensive treatment to reduce residual modifiable risk, we believe that substantial improvements in cardiovascular disease prevention could be achieved in clinical practice.
- Top Cited PapersOpen Access
- 24 July 2002
- Published by American Medical Association (AMA) in JAMA
- Vol. 288 (4) , 455-461
Long-term Persistence in Use of Statin Therapy in Elderly Patients
Cardiovascular disease accounts for 950 000 deaths annually in the United States, including 460 000 deaths from coronary heart disease (CHD).1 Eighty-five percent of those who die of CHD and 72% of those who experience a stroke each year are 65 years of age and older.1 Since 1994, 6 large clinical trials have shown that 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) significantly reduce the incidence of CHD-related morbidity and mortality and strokes in patients undergoing treatment for an average of 5 years.2-7 Analyses suggest that the benefits of statin treatment in patients 65 years of age and older are quite similar to those seen in younger patients.7-10 The recent National Cholesterol Education Program Adult Treatment Panel III recommendations expanded the treatment-eligible elderly population from 4.2 million to 9.7 million individuals11 and emphasized that adherence to lipid-lowering therapy is critical to achieving the full population effectiveness of primary and secondary prevention.12
- 24 July 2002
- Published by American Medical Association (AMA) in JAMA
- Vol. 288 (4) , 455-461
Top Cited PapersOpen AccessLong-term Persistence in Use of Statin Therapy in Elderly Patients
Cardiovascular disease accounts for 950 000 deaths annually in the United States, including 460 000 deaths from coronary heart disease (CHD).1 Eighty-five percent of those who die of CHD and 72% of those who experience a stroke each year are 65 years of age and older.1 Since 1994, 6 large clinical trials have shown that 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) significantly reduce the incidence of CHD-related morbidity and mortality and strokes in patients undergoing treatment for an average of 5 years.2-7 Analyses suggest that the benefits of statin treatment in patients 65 years of age and older are quite similar to those seen in younger patients.7-10 The recent National Cholesterol Education Program Adult Treatment Panel III recommendations expanded the treatment-eligible elderly population from 4.2 million to 9.7 million individuals11 and emphasized that adherence to lipid-lowering therapy is critical to achieving the full population effectiveness of primary and secondary prevention.12